CTI BioPharma to Present at the 43rd Annual Cowen Health Care Conference

CTI BioPharma Corp. (Nasdaq: CTIC) will present a corporate overview at the 43rd Annual Cowen Health Care Conference on March 8, 2023, at 10:30 a.m. ET.

Rhea-AI Summary

CTI BioPharma Corp. (Nasdaq: CTIC) will present a corporate overview at the 43rd Annual Cowen Health Care Conference on March 8, 2023, at 10:30 a.m. ET. The presentation will cover the company's focus on developing targeted therapies for blood-related cancers, highlighted by their FDA-approved product, VONJO® (pacritinib), which treats myelofibrosis in patients with severe thrombocytopenia. Investors can access the live and archived webcast on the CTI BioPharma website under the Investors & Media section.

Argus Session date unavailable

-0.18% session move Open Argus

Details

News Market Reaction – CTIC

The recorded move for CTIC in the trading session of this news was -0.18%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, March 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that the management team will present a corporate overview at the 43^rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET (7:30 a.m. PT).

A link to the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations.

About CTI BioPharma Corp.

CTI BioPharma is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO® (pacritinib), a JAK2, ACVR1,­­ and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. For more information, please visit www.ctibiopharma.com.

VONJO® is a registered trademark of CTI BioPharma Corp.

Investor Relations and Media Contacts:

Remy Bernarda
Jenny Kobin
invest@ctibiopharma.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-43rd-annual-cowen-health-care-conference-301760024.html

SOURCE CTI BioPharma Corp.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will CTI BioPharma present at the 43rd Annual Cowen Health Care Conference?

CTI BioPharma will present a corporate overview highlighting its developments in blood-related cancer therapies, including its FDA-approved product, VONJO®.

When is CTI BioPharma's presentation at the Cowen Health Care Conference?

CTI BioPharma's presentation is scheduled for March 8, 2023, at 10:30 a.m. ET.

Where can I watch the CTI BioPharma presentation?

The presentation can be accessed live and in archive on the CTI BioPharma website under the Investors & Media section.

What is VONJO® and its approval status?

VONJO® (pacritinib) is an FDA-approved treatment for adults with intermediate- or high-risk myelofibrosis and severe thrombocytopenia.

What is the focus of CTI BioPharma's development efforts?

CTI BioPharma focuses on developing targeted therapies for blood-related cancers.